Pluristem Therapeutics Inc. (Nasdaq: PSTI) reported positive data from preclinical studies of its PLX-PAD cells in the treatment of Duchenne ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE